p53 protein expression in ductal carcinoma in situ (DCIS) of the breast

Breast Cancer Research and Treatment

Volumn 42, Issue 3, 1997, Pages 283-290

  Rajan, Prabha B ^a,b   Scott, David J ^a   Perry, Robert H ^a   Griffith, Clive D M ^a  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Breasts ductal carcinoma in situ; p53; Tumour suppressor gene

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

ARTICLE; BREAST CANCER; CARCINOMA IN SITU; COMEDO; FAMILIAL CANCER; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MITOSIS INDEX; MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; TUMOR RECURRENCE;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; PEROXIDASES; PROGNOSIS; STAINING AND LABELING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031040393     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005741723479     Document Type: Article

References (47)

1. Isobe M, Emanuel BS, Gival D, Oren M, Croce CM: Localization of gene for human p53 tumor antigen to band 17 p 13. Nature 320: 84-85, 1986
2. Nigro JM, Baker SJ, Presinger AC, Jessup JM, Hosteller R, Cleary K: Mutations in the p53 gene occur in diverse human tumor types. Nature 342: 705-708, 1989
3. Toguchida J, Ishizaki K, Nakamura YK, Sasaki MS, Ikonaga M, Kato M: Assignment of common allele loss in osteosarcoma to the subregion 17 p 13. Cancer Res 49: 6247-6251, 1989
4. Jaros E, Perry RH, Adams L, Kelly PJ, Crawford PJ, Kalbag AD: Prognostic implications of p53 protein, epidermal growth factor receptor, Ki 67 labelling in brain tumours. Br J Cancer 66: 373-385, 1992
5. Li FP, Fraumeni JF: Soft tissue sarcomas, breast cancer and other neoplasms, a familial syndrome. Ann Intern Med 71: 747-751, 1969
6. Li FP, Fraumeni JF, Mulvihill JJ Jr, Blattner WA, Dreyfus MG, Tucker MA: A cancer family syndrome in twenty-four kindreds. Cancer Res 48: 5358-5362, 1988
7. Lane DP, Benchimol S: p53: oncogene or antioncogene. Genes Dev 4: 1-8, 1990
8. Lane DP, Crawford LV: T antigen is bound to host protein in SV 40 transformed cells. Nature 278: 261-263, 1979
9. Varley MJ, Brammar WJ, Lane DP, Swallow JE, Dolan C, Walker RA: Loss of chromosome 17 p 13 sequences and mutation of p53 in human breast carcinomas. Oncogene 3: 413-421, 1991
10. Page DL, Anderson TJ, Rogers LW: Carcinoma in situ. In: Page DL, Anderson TJ (eds) Diagnostic Histopathology of the Breast. 1st ed. Churchill Livingstone, Edinburgh, UK, 1987, pp 157-192
11. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957
12. Elston CW: Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ (eds) Diagnostic Histopathology of the Breast. 1st ed. Churchill Livingstone, Edinburgh, UK, 1987, pp 300-311
13. Killeen JI, Namiki H: DNA analysis of ductal carcinoma in situ. Cancer 68: 2602-2608, 1991
14. Bellamy COC, McDonald C, Anderson TJ, Slater DM, Chetty U: Non-invasive ductal carcinoma of the breast. Hum Pathol 24: 16-23, 1993
15. Van Diest PJ, Baak JPA, Matze-Cok P, Wisse-Brekelmans ECM, VanGalen CM, Karver PHJ: Reproducibility of mitosis counting in 2469 breast cancer specimens. Hum Pathol 23: 603-607, 1992
16. Baak JPA: Mitosis counting in tumors. Hum Pathol 21: 683-685, 1990
17. Westra WH, Offerhaus GJA, Goodman SN, Slabas RJC, Polak M, Baas IO: Overexpression of the p53 suppressor gene product in primary adenocarcinoma is associated with cigarette smoking. Am J Surg Pathol 17: 213-220, 1993
18. Mercer WE, Avignolo C, Baserga R: Role of p53 protein in cell proliferation as studied by microinjection of monoclonal antibodies. Mol Cell Biol 4: 276-281, 1984
19. Parada LF, Land H, Weinberg RA, Wolf D, Rotter V: Cooperation between gene encoding p53 tumor antigen and ras in cellular transformation. Nature 312: 649-651, 1984
20. Finley CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ: Activating mutations for transformation by p53 produce a gene product that forms an hsc to p53 complex with an altered half-life. Mol Cell Biol 8: 531-539, 1988
21. Banks L, Matloshewski C, Crawford L: Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159: 529-534, 1986
22. Gannon JV, Greaves R, Iggo R: Activating mutations in p53 produce a common effect. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595-1602, 1990
23. Davidoff AM, Kerns BS, Pence JC, Marks JR, Iglehart JD: p53 alterations in all stages of breast cancer. J Surg Oncol 48: 260-267, 1991
24. Davidoff AM, Herridon JE, Kerns BJ, Glover NS, Pence JC, Iglehart D: Relation between p53 Overexpression and established prognostic factors in breast cancer. Surgery 110: 259-264, 1991
25. Davidoff AM, Kerns BJ, Iglehart JD, Marks JR: Maintenance of p53 alteration throughout breast cancer progression. Cancer Res 51: 2605-2610, 1991
26. Iggo R, Gatter K, Bartek J, Lane D, Harns AL: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335: 675-679, 1990
27. Bur ME, Perlman C, Edelman L, Fey E, Rose PG: p53 expression in neoplasms of uterine corpus. Am J Clin Pathol 98: 81-87, 1992
28. Sidransky D, Von Eschenbach L, Tsai YC, James P, Summerhayes I, Marshall F: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706-707, 1991
29. Vogelstein B: A deadly inheritance. Nature 348: 681-682, 1990
30. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990
31. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT: Accumulation of p53 tumor suppressor gene protein. An independent marker of prognosis in breast cancers. J Nat Cancer Inst 84: 845-855, 1992
32. Tsuda H, Iwaya K, Fakutomi T, Hirohashi S: p53 mutations and c-erbB-2 amplification in intraductal and invasive carcinomas of high histologie grade. Jpn J Cancer Res 84: 394-401, 1993
33. Poller DN, Roberts EC, Elston CW, Blamey RW, Ellis IO: p53 protein expression in mammary ductal carcinoma in situ. Hum Pathol 24: 463-468, 1993
34. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Lane DP: Patterns of expression of the p53 tumor suppressor in human breast tissues and tumors in situ and in vitro. Int J Cancer 46: 839-844, 1990
35. Bhargava V, Thor A, Deng G, Ljung B, Moore DH, Waldman F, Benz C, Goodson W, Mayall B, Chew K, Smith HS: The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Modern Pathol 7: 361-369, 1994
36. Zafrani B, Leroger A, Fourquet A, Laurent M, Trophilme D, Pierre V, Sastra-Garaux: Mammographically-detected ductal in situ carcinoma of the breast. Analysis with a new classification. A study of 127 cases: Correlation with estrogen and progesterone receptors, p53 and C-erbB-2 proteins, and proliferative activity. Seminars in Diagnostic Pathol 11: 208-214, 1994
37. Bobrow L, Happerfield LC, Gregory WM, Springall RD, Millis RR: The classification of ductal carcinoma in situ and its association with biological markers. Seminars in Diagnostic Pathol 11: 199-207, 1994
38. Lagios MD: Duclal carcinoma in situ. Pathology and treatment. Surg Clin North America 70: 853-871, 1990
39. O'Malley FP, DuPont WD, Page DL, Vnencak-Jones CL, Pari F, Manning S, Page DL: p53 mutation are confined to the comedo type ductal carcinoma in situ of the breast. Lab Invest 71: 67-72, 1994
40. Van Dongen JA, Holland R, Peterse JL: Ductal carcinoma in situ of the breast. Second EORTC consensus meeting. Eur J Cancer 28: 626-629, 1992
41. Cattoretti G, Rilke F, Andreola S, Amato LD, Delin D: p53 expression in breast cancer. Int J Cancer 4: 178-183, 1988
42. Crawford LV, Pim DC, Lamb P: The cellular protein p53 in human tumors. Mol Biol Med 2: 261-272, 1984
43. Ostrowsky JL, Sawan A, Henry JA, Li JJW, Angus B, Horne CHW: p53 expression in human breast cancer related to survival and prognostic factors. An immunohistochemical study. J Pathol 164: 75-81, 1991
44. Walker RA, Dearing SJ, Lane DP, Varley JM: Expression of p53 protein in infiltrating and in situ breast carcinomas. J Pathol 165: 203-211, 1991
45. Woosley J: Measuring cell proliferation. Arch Pathol Lab Med 115: 555-557, 1991
46. Simpson JF, Dutt PL, Page DL: Expression of mitosis per thousand cell density in breast carcinomas, A proposal. Hum Pathol 23: 608-611, 1992
47. Laroye GJ, Minkin S: The impact of mitotic index on predicting outcome in breast carcinoma. A comparison of different methods in patients with different lymph node status. Mod Pathol 4: 456-460, 1991